Download PDF
Horm Metab Res 2012; 44(10): 713-715
DOI: 10.1055/s-0031-1301327
Editorial
© Georg Thieme Verlag KG Stuttgart · New York

Cyclic AMP, Protein Kinase A, and Phosphodiesterases: Proceedings of an International Workshop

C. A. Stratakis
1   Section of Endocrinology and Genetics, Program on Developmental Endocrinology Genetics, Eunice Kennedy Shriver National Institute of Child Health and Human Development, National Institutes of Health, Bethesda, Maryland, USA
› Author Affiliations
Further Information

Publication History

received 09 January 2012

accepted 09 January 2012

Publication Date:
05 September 2012 (online)

Also available at
    Permissions and Reprints

Abstract

Cyclic nucleotides cAMP and cGMP are part of almost all major cellular signaling pathways. Phosphodiesterases (PDEs) are enzymes that regulate the intracellular levels of cAMP and cGMP. Protein kinase A or cAMP-dependent protein kinase mediates most cAMP effects in the cell. Over the last 25 years, various components of this group of molecules have been involved in human diseases, both genetic and acquired. Lately, the PDEs attract more attention. The pharmacological exploitation of the PDE’s ability to regulate cGMP and cAMP, and through them, a variety of signaling pathways, has led to a number of new drugs for diverse applications from the treatment of erectile dysfunction to heart failure, asthma, and chronic obstructive pulmonary disease. We present the abstracts (available online) and selected articles from the proceedings of a meeting that took place at the National Institutes of Health (NIH), Bethesda, MD, June 8–10, 2011.

 

  • References

  • 1 Savai R, Pullamsetti SS, Banat GA, Weissmann N, Ghofrani HA, Grimminger F, Schermuly RT. Targeting cancer with phosphodiesterase inhibitors. Expert Opin Investig Drugs 2010; 19: 117-131
    CrossrefPubMedGoogle Scholar
  • 2 Makhlouf A, Kshirsagar A, Niederberger C. Phosphodiesterase 11: a brief review of structure, expression and function. Int J Impot Res 2006; 18: 501-509
    CrossrefPubMedGoogle Scholar
  • 3 Taskén K, Skålhegg BS, Taskén KA, Solberg R, Knutsen HK, Levy FO, Sandberg M, Orstavik S, Larsen T, Johansen AK, Vang T, Schrader HP, Reinton NT, Torgersen KM, Hansson V, Jahnsen T. Structure, function, and regulation of human cAMP-dependent protein kinases. Adv Second Messenger Phosphoprotein Res 1997; 31: 191-204
    CrossrefPubMedGoogle Scholar
  • 4 Kim C, Xuong NH, Taylor SS. Crystal structure of a complex between the catalytic and regulatory (RIalpha) subunits of PKA. Science 2005; 307 (5710) 690-696
    Google Scholar
  • 5 Kim C, Cheng CY, Saldanha SA, Taylor SS. PKA-I holoenzyme structure reveals a mechanism for cAMP-dependent activation. Cell 2007; 130: 1032-1043
    Google Scholar
  • 6 Francis SH, Corbin JD. Cyclic nucleotide-dependent protein kinases: intracellular receptors for cAMP and cGMP action. Crit Rev Clin Lab Sci 1999; 36: 275-328
    CrossrefPubMedGoogle Scholar
  • 7 Kim MJ, Lee JH, Park SY, Hong KW, Kim CD, Kim KY, Lee WS. Protection from apoptotic cell death by cilostazol, phosphodiesterase type III inhibitor, via cAMP-dependent protein kinase activation. Pharmacol Res 2006; 54: 261-267
    CrossrefPubMedGoogle Scholar
  • 8 Zhang L, Murray F, Zahno A, Kanter JR, Chou D, Suda R, Fenlon M, Rassenti L, Cottam H, Kipps TJ, Insel PA. Cyclic nucleotide phosphodiesterase profiling reveals increased expression of phosphodiesterase 7B in chronic lymphocytic leukemia. Proc Natl Acad Sci USA 2008; 105: 19532-19537
    CrossrefPubMedGoogle Scholar
  • 9 Sengupta R, Sun T, Warrington NM, Rubin JB. Treating brain tumors with PDE4 inhibitors. Trends Pharmacol Sci 2011; 32: 337-344
    CrossrefPubMedGoogle Scholar
  • 10 Jeon YH, Heo YS, Kim CM, Hyun YL, Lee TG, Ro S, Cho JM. Phosphodiesterase: overview of protein structures, potential therapeutic applications and recent progress in drug development. Cell Mol Life Sci 2005; 62: 1198-1220
    CrossrefPubMedGoogle Scholar
  • 11 Bender AT, Beavo JA. Cyclic nucleotide phosphodiesterases: molecular regulation to clinical use. Pharmacol Rev 2006; 58: 488-520
    CrossrefPubMedGoogle Scholar
  • 12 Weinstein LS, Shenker A, Gejman PV, Merino MJ, Friedman E, Spiegel AM. Activating mutations of the stimulatory G protein in the McCune-Albright syndrome. N Engl J Med 1991; 325: 1688-1695
    Google Scholar
  • 13 Kirschner LS, Carney JA, Pack SD, Taymans SE, Giatzakis C, Cho YS, Cho-Chung YS, Stratakis CA. Mutations of the gene encoding the protein kinase A type I-alpha regulatory subunit in patients with the Carney complex. Nat Genet 2000; 26: 89-92
    Google Scholar
  • 14 Carney JA, Gordon H, Carpenter PC, Shenoy BV, Go VL. The complex of myxomas, spotty pigmentation, and endocrine overactivity. Medicine (Baltimore) 1985; 64: 270-283
    CrossrefPubMedGoogle Scholar
  • 15 Bertherat J, Horvath A, Groussin L, Grabar S, Boikos S, Cazabat L, Libé R, Rene-Corail F, Stergiopoulos S, Bourdeau I, Bei T, Clauser E, Calender A, Kirschner LS, Bertagna X, Carney JA, Stratakis CA. Mutations in regulatory subunit type 1 A of cyclic adenosine 5-monophosphate-dependent protein kinase (PRKAR1A): phenotype analysis in 353 patients and 80 different genotypes. J Clin Endocrinol Metab 2009; 94: 2085-2091
    CrossrefPubMedGoogle Scholar
  • 16 Greene EL, Horvath AD, Nesterova M, Giatzakis C, Bossis I, Stratakis CA. In vitro functional studies of naturally occurring pathogenic PRKAR1A mutations that are not subject to nonsense mRNA decay. Hum Mutat 2008; 29: 633-639
    Google Scholar
  • 17 Groussin L, Kirschner LS, Vincent-Dejean C, Perlemoine K, Jullian E, Delemer B, Zacharieva S, Pignatelli D, Carney JA, Luton JP, Bertagna X, Stratakis CA, Bertherat J. Molecular analysis of the cyclic AMP-dependent protein kinase A (PKA) regulatory subunit 1 A (PRKAR1A) gene in patients with Carney complex and primary pigmented nodular adrenocortical disease (PPNAD) reveals novel mutations and clues for pathophysiology: augmented PKA signaling is associated with adrenal tumorigenesis in PPNAD. Am J Hum Genet 2002; 71: 1433-1442
    CrossrefPubMedGoogle Scholar
  • 18 Horvath A, Bertherat J, Groussin L, Guillaud-Bataille M, Tsang K, Cazabat L, Libé R, Remmers E, Rene-Corail F, Faucz FR, Clauser E, Calender A, Bertagna X, Carney JA, Stratakis CA. Mutations and polymorphisms in the gene encoding regulatory subunit type 1-alpha of protein kinase A (PRKAR1A): an update. Hum Mutat 2010; 31: 369-379
    CrossrefPubMedGoogle Scholar
  • 19 Rothenbuhler A, Stratakis CA. Clinical and molecular genetics of Carney complex. Best Pract Res Clin Endocrinol Metab 2010; 24: 389-399
    CrossrefPubMedGoogle Scholar
  • 20 Bertherat J, Groussin L, Sandrini F, Matyakhina L, Bei T, Stergiopoulos S, Papageorgiou T, Bourdeau I, Kirschner LS, Vincent-Dejean C, Perlemoine K, Gicquel C, Bertagna X, Stratakis CA. Molecular and functional analysis of PRKAR1A and its locus (17q22–24) in sporadic adrenocortical tumors: 17q losses, somatic mutations, and protein kinase A expression and activity. Cancer Res 2003; 63: 5308-5319
    Google Scholar
  • 21 Horvath A, Boikos S, Giatzakis C, Robinson-White A, Groussin L, Griffin KJ, Stein E, Levine E, Delimpasi G, Hsiao HP, Keil M, Heyerdhal S, Matyakhina L, Libé R, Fratticci A, Kirschner LS, Craner K, Gaillard RC, Bertagna X, Carney JA, Bertherat J, Bossis I, Stratakis CA. A genome-wide scan identifies mutations in the gene encoding phosphodiesterase 11A4 (PDE11A) in individuals with adrenocortical hyperplasia. Nat Genet 2006; 38: 794-800
    CrossrefPubMedGoogle Scholar
  • 22 Horvath A, Giatzakis C, Robinson-White A, Boikos S, Levine E, Griffin K, Stein E, Kamvissi V, Soni P, Bossis I, De Herder W, Carney JA, Bertherat J, Gregersen PK, Remmers EF, Stratakis CA. Adrenal hyperplasia and adenomas are associated with inhibition of phosphodiesterase 11A in carriers of PDE11A sequence variants that are frequent in the population. Cancer Res 2006; 66: 11571-11575
    CrossrefPubMedGoogle Scholar
  • 23 Libé R, Fratticci A, Coste J, Tissier F, Horvath A, Ragazzon B, Rene-Corail F, Groussin L, Bertagna X, Raffin-Sanson ML, Stratakis CA, Bertherat J. Phosphodiesterase 11A (PDE11A) and genetic predisposition to adrenocortical tumors. Clin Cancer Res 2008; 14: 4016-4024
    CrossrefPubMedGoogle Scholar
  • 24 Libé R, Horvath A, Vezzosi D, Fratticci A, Coste J, Perlemoine K, Ragazzon B, Guillaud-Bataille M, Groussin L, Clauser E, Raffin-Sanson ML, Siegel J, Moran J, Drori-Herishanu L, Faucz FR, Lodish M, Nesterova M, Bertagna X, Bertherat J, Stratakis CA. Frequent phosphodiesterase 11A gene (PDE11A) defects in patients with Carney complex (CNC) caused by PRKAR1A mutations: PDE11A may contribute to adrenal and testicular tumors in CNC as a modifier of the phenotype. J Clin Endocrinol Metab 2011; 96: E208-E214
    CrossrefPubMedGoogle Scholar
  • 25 Faucz FR, Horvath A, Rothenbuhler A, Almeida MQ, Libé R, Raffin-Sanson ML, Bertherat J, Carraro DM, Soares FA, GdeC Molina, Canpos AH, Alexandre RB, Bendhak ML, Nesterova M, Stratakis CA. Phosphodiesterase 11A (PDE11A) genetic variants may increase susceptibility to prostatic cancer. J Clin Endocrinol Metab 2011; 96: E135-E140
    CrossrefPubMedGoogle Scholar
  • 26 Horvath A, Giatzakis C, Tsang K, Greene E, Osorio P, Boikos S, Libé R, Patronas Y, Robinson-White A, Remmers E, Bertherat J, Nestrova M, Stratakis CA. A cAMP-specific phosphodiesterase (PDE8B) that is mutated in adrenal hyperplasia is expressed widely in human and mouse tissues: a novel PDE8B isoform in human adrenal cortex. Eur J Hum Genet 2008; 16: 1245-1253
    CrossrefPubMedGoogle Scholar
  • 27 Tsai LC, Shimizu-Albergine M, Beavo JA. The high-affinity cAMP-specific phosphodiesterase 8B controls steroidogenesis in the mouse adrenal gland. Mol Pharmacol 2011; 79: 639-648
    CrossrefPubMedGoogle Scholar
  • 28 Horvath A, Mericq V, Stratakis CA. Mutation in PDE8B, a cyclic AMP-specific phosphodiesterase in adrenal hyperplasia. N Engl J Med 2008; 358: 750-752
    CrossrefPubMedGoogle Scholar
  • 29 Rothenbuhler A, Horvath A, Faucz F, Almeida M, Lodish M, Libé R, Nesterova M, Bertherat J, Stratakis CA. Three novel mutations in PDE8B, a cAMP phosphodiesterase highly expressed in the adrenal cortex, in a cohort of patients with adrenal tumors. Program of the 91st Annual Meeting of the Endocrine Society, Washington, DC 2009;
    PubMedGoogle Scholar
  • 30 Bimpaki EI, Nesterova M, Stratakis CA. Abnormalities of cAMP signaling are present in adrenocortical lesions associated with ACTH-independent Cushing syndrome despite the absence of mutations in known genes. Eur J Endocrinol 2009; 161: 153-161
    CrossrefPubMedGoogle Scholar
  • 31 Hayashi M, Matsushima K, Ohashi H, Tsunoda H, Murase S, Kawarada Y, Tanaka T. Molecular cloning and characterization of human PDE8B, a novel thyroid-specific isozyme of 3′,5′-cyclic nucleotide phosphodiesterase. Biochem Biophys Res Commun 1998; 250: 751-756
    CrossrefPubMedGoogle Scholar
  • 32 Arnaud-Lopez L, Usala G, Ceresini G, Mitchell BD, Pilia MG, Piras MG, Sestu N, Maschio A, Busonero F, Albai G, Dei M, Lai S, Mulas A, Crisponi L, Tanaka T, Bandinelli S, Guralnik JM, Loi A, Balaci L, Sole G, Prinzis A, Mariotti S, Shuldiner AR, Cao A, Schlessinger D, Uda M, Abecasis GR, Nagaraja R, Sanna S, Naitza S. Phosphodiesterase 8B gene variants are associated with serum TSH levels and thyroid function. Am J Hum Genet 2008; 82: 1270-1280
    CrossrefPubMedGoogle Scholar
  • 33 Volpato CB, De Grandi A, Gögele M, Taliun D, Fuchsberger C, Facheris MF, Minelli C, Pattaro C, Pramstaller PP, Hicks AA. Linkage and association analysis of hyperthyrotropinaemia in an Alpine population reveal two novel loci on chromosomes 3q28–29 and 6q26–27. J Med Genet 2011; 48: 549-556
    CrossrefPubMedGoogle Scholar
  • 34 Lania A, Persani L, Ballaré E, Mantovani S, Losa M, Spada A. Constitutively active Gs alpha is associated with an increased phosphodiesterase activity in human growth hormone-secreting adenomas. J Clin Endocrinol Metab 1998; 83: 1624-1628
    CrossrefPubMedGoogle Scholar
  • 35 Knight WE, Yan C. Cardiac cyclic nucleotide phosphodiesterase: function, regulation, and therapeutic prospects. Horm Metab Res 2012; 44: 766-775
    Article in Thieme ConnectPubMedGoogle Scholar
  • 36 Mantovani G, Elli FM, Spada A. GNAS epigenetic defects and pseudohypoparathyroidism: time for a new classification?. Horm Metab Res 2012; 44: 716-723
    Google Scholar
  • 37 Zhang S, Kaplan FS, Shore EM. Different roles of GNAS and cAMP signaling during early and late stages of osteogenic differentiation. Horm Metab Res 2012; 44: 724-731
    Google Scholar
  • 38 Silve C, Clauser E, Linglart A. Acrodysostosis. Horm Metab Res 2012; 44: 749-758
    Google Scholar
  • 39 Yu B, Ragazzon B, Rizk-Rabin M, Bertherat J. Protein kinase A alterations in endocrine tumors. Horm Metab Res 2012; 44: 741-748
    Article in Thieme ConnectPubMedGoogle Scholar
  • 40 Tsai LC, Beavo JA. Regulation of adrenal steroidogenesis by the high-affinity phosphodiesterase 8 family. Horm Metab Res 2012; 44: 790-794
    Article in Thieme ConnectPubMedGoogle Scholar
  • 41 Bastepe M. Relative functions of Gαs and its extra-large variant XLαs in the endocrine system. Horm Metab Res 2012; 44: 732-740
    Article in Thieme ConnectPubMedGoogle Scholar
  • 42 Ahmad F, Degerman E, Manganiello VC. Cyclic nucleotide phosphodiesterase 3 signaling complexes. Horm Metab Res 2012; 44: 776-785
    Article in Thieme ConnectPubMedGoogle Scholar
  • 43 Hussain MA, Stratakis CA, Kirschner L. Prkar1a in the regulation of insulin secretion. Horm Metab Res 2012; 44: 759-765
    Article in Thieme ConnectPubMedGoogle Scholar
  • 44 Vincent P, Castro LR, Gervasi N, Guiot E, Brito M, Paupardin-Tritsch D. PDE4 control on cAMP/PKA compartmentation revealed by biosensor imaging in neurons. Horm Metab Res 2012; 44: 786-789
    Article in Thieme ConnectPubMedGoogle Scholar